Supernus (INDV) EV to FCF (2024 - 2026)
Indivior Pharmaceuticals' EV to FCF came in at 126.64 for Q3 2026, up 487.5% from 21.56 a year earlier.
Supernus (INDV) EV to FCF (2024 - 2026) Analysis & Trends
Over the trailing twelve months to Sep 30, 2026, Indivior Pharmaceuticals reported EV to FCF of 107.54, up 839.5% year-over-year; for FY2024, it came in at 175.64.
- Going back by year, EV to FCF was 4.04 in FY2021.
- The Q3 2026 figure represents the highest quarterly EV to FCF since Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn |
| 10 | Supernus | 4.28 Bn | 3.38 Bn | 305.00 Mn |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 126.64 |
| Sep 30, 2025 | 21.56 |
| Jun 30, 2025 | 7.68 |
| Mar 31, 2025 | 7.03 |
| Dec 31, 2024 | 175.64 |
Supernus EV to FCF API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-fcf&ticker=INDV&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-fcf", "ticker": "INDV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-fcf&ticker=INDV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();